Open Access Gold möglich sobald Verlagsversion bei der ZB eingereicht worden ist.
Unveiling therapeutic targets for esophageal cancer: A comprehensive review.
Curr. Oncol. 30, 9542-9568 (2023)
Esophageal cancer is a highly aggressive and deadly disease, ranking as the sixth leading cause of cancer-related deaths worldwide. Despite advances in treatment, the prognosis remains poor. A multidisciplinary approach is crucial for achieving complete remission, with treatment options varying based on disease stage. Surgical intervention and endoscopic treatment are used for localized cancer, while systemic treatments like chemoradiotherapy and targeted drug therapy play a crucial role. Molecular markers such as HER2 and EGFR can be targeted with drugs like trastuzumab and cetuximab, and immunotherapy drugs like pembrolizumab and nivolumab show promise by targeting immune checkpoint proteins. Epigenetic modifications offer new avenues for targeted therapy. Treatment selection depends on factors like stage, tumor location, and patient health, with post-operative and rehabilitation care being essential. Early diagnosis, appropriate treatment, and supportive care are key to improving outcomes. Continued research is needed to develop effective targeted drugs with minimal side effects. This review serves as a valuable resource for clinicians and researchers dedicated to enhancing esophageal cancer treatment outcomes.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Schlagwörter
Esophageal Cancer ; Molecular Markers ; Multidisciplinary Approach ; Prognosis ; Targeted Therapy; Quality-of-life; Endoscopic Submucosal Dissection; Minimally Invasive Mckeown; Endothelial Growth-factor; Squamous-cell Carcinoma; Term-follow-up; Mucosal Resection; Esophagogastric Junction; Barretts-esophagus; Management
ISSN (print) / ISBN
1198-0052
e-ISSN
1718-7729
Zeitschrift
Current Oncology
Quellenangaben
Band: 30,
Heft: 11,
Seiten: 9542-9568
Verlag
MDPI
Verlagsort
St Alban-anlage 66, Ch-4052 Basel, Switzerland
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Institut(e)
Lung Health and Immunity (LHI)